Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer’s disease

• Published in: Alzheimer's research & therapy Vol. 16; no. 1; pp. 82 - 18
• Main Authors: Wang, Xiaoling, Zhang, Xiaomin, Liu, Jing, Zhang, Jingjing, Liu, Congcong, Cui, Yuting, Song, Qiao, Hou, Yuli, Wang, Yaqi, Zhang, Qian, Zhang, Yingzhen, Fan, Yujian, Jia, Jianping, Wang, Peichang
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 13.04.2024; BioMed Central; BMC
• Subjects: Alzheimer Disease - diagnosis; Alzheimer Disease - genetics; Alzheimer's disease; Analysis; Antibodies; Antigens; APOE ε4 carriers; Apolipoprotein E4; Apolipoproteins; Biological markers; Biomarkers; Care and treatment; Cognition & reasoning; Cognitive ability; Dementia; Diagnosis; Dosage and administration; Early Diagnosis; Glycoproteins; Humans; Hyperglycemia; Hypertension; Levetiracetam; Medical diagnosis; Membrane Glycoproteins - cerebrospinal fluid; Membrane Glycoproteins - chemistry; Nerve Tissue Proteins - cerebrospinal fluid; Nerve Tissue Proteins - chemistry; Serum SV2A; Simoa; Synaptic Vesicles - chemistry; Synaptic Vesicles - metabolism; Systemic diseases; China; Early diagnosis; Serum SV2A; Simoa; APOE ε4 carriers; Alzheimer’s disease

Previous studies have demonstrated that early intervention was the best plan to inhibit the progression of Alzheimer's disease (AD), which relied on the discovery of early diagnostic biomarkers. In this study, synaptic vesicle glycoprotein 2 A (SV2A) was examined to improve the early diagnostic...